HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia.
Chronic myeloid leukemia (CML) is characterized by the chromosomal translocation t (9 ; 22) resulting in the chimeric bcr-abl oncogene that encodes the P210 fusion protein, which contains a unique amino acid sequence.
If peptides derived from the leukemia-specific part of P210 are expressed in HLA molecules on the cell membrane of leukemic cells, an immunological response may occur.
Recent studies using synthetic peptides identical to the bcr-abl fusion region showed that some peptides are capable of binding to HLA-A3, - A11, and - B8 molecules.
Cytotoxic T-cell responses have been induced against bcr-abl-derived synthetic peptides bound to HLA-A3 and - B8.
We hypothesized that if antigen processing of the P210 fusion protein leads to presentation of peptides from the fusion region by major histocompatibility complex (MHC) molecules in vivo, this may be reflected in a diminished incidence of CML in individuals expressing HLA-A3, - All, or - B8.
Consequently, lower frequencies of these antigens would be expected in patients with CML compared with unaffected individuals.
A case-control study and a meta-analysis were performed to test this hypothesis.
The multicenter case-control study compared patients with CML from the data base of the European Group for Blood and Marrow Transplantation (EBMT) with unaffected individuals from the registry of Bone Marrow Donors Worldwide.
Patients and controls were matched per country. (...)
Mots-clés Pascal : Leucémie myéloïde, Facteur risque, Antigène histocompatibilité classe I, Système HLA, Système histocompatibilité majeur, Epidémiologie, Etude cas témoin, Etude multicentrique, Métaanalyse, Homme, Chronique, Hémopathie maligne, Myéloprolifératif syndrome
Mots-clés Pascal anglais : Chronic myelocytic leukemia, Risk factor, Class I histocompatibility antigen, HLA-System, Major histocompatibility system, Epidemiology, Case control study, Multicenter study, Metaanalysis, Human, Chronic, Malignant hemopathy, Myeloproliferative syndrome
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0320601
Code Inist : 002B19B. Création : 16/11/1999.